Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
The Pharmaceutical Market: Czech Republic
Management Report
Published: January 2010
Pages: 78
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00 Buy Now!
Research from: Espicom
Sector: Prescription Medicines
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
The Czech Republic was one of the larger countries to join the EU in May 2004 and it has the third largest pharmaceutical market in the region. Local production of generics is strong, and was enhanced in 2003 by the merger of the leading Czech manufacturer, Leciva, with its Slovak counterpart, Slovakofarma, to form Zentiva. There is little branded manufacturing in the Czech Republic. The Czech Republic is easily reached from other EU countries such as Germany or Austria, and the market is increasingly dominated by imported products.
The country has a history of high drug consumption, a legacy of many years of reliance on cheap generics. In January 2008, the government introduced new fees for prescriptions and visits to the doctor that could result in reduced pharmaceutical sales. The opposition argues that the fees violate the law which guarantees medical care for every citizen. People aged under 18 years are now exempt from the fees.
Healthcare funding is largely public, through health insurance. Provision of care is also largely public; the Czech Republic has yet to develop a substantial private sector. Private spending only accounts for around 12.1% of the total in 2010. One of the reasons for the new fees introduced in 2008 was to increase funding for the healthcare system.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data
The country has a history of high drug consumption, a legacy of many years of reliance on cheap generics. In January 2008, the government introduced new fees for prescriptions and visits to the doctor that could result in reduced pharmaceutical sales. The opposition argues that the fees violate the law which guarantees medical care for every citizen. People aged under 18 years are now exempt from the fees.
Healthcare funding is largely public, through health insurance. Provision of care is also largely public; the Czech Republic has yet to develop a substantial private sector. Private spending only accounts for around 12.1% of the total in 2010. One of the reasons for the new fees introduced in 2008 was to increase funding for the healthcare system.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data